Concerned about prescribing Entyvio because of coverage?
Entyvio is covered by 99%* of commercial insurance plans.1†

Size of insured population does not imply prevalence or appropriate population for treatment with Entyvio. Coverage status is subject to change without notice.

*
55% covered, 35% covered with 1 step, 9% covered with 2 steps.
As of October 31, 2016.

Indications

Adult Ulcerative Colitis (UC) ENTYVIO (vedolizumab) is indicated in adult patients with moderately to severely active UC who have had an inadequate response with, lost response to, or were intolerant to a tumor necrosis factor (TNF) blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids for inducing and maintaining clinical response, inducing and maintaining clinical remission, improving endoscopic appearance of the mucosa, and achieving corticosteroid‐free remission.
Adult Crohn’s Disease (CD) ENTYVIO (vedolizumab) is indicated in adult patients with moderately to severely active CD who have had an inadequate response with, lost response to, or were intolerant to a TNF blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids for achieving clinical response, achieving clinical remission, and achieving corticosteroid‐free remission.

The Entyvio Connect program puts you in touch with case managers, who will guide you and your patients through the insurance and financial assistance process

If you think Entyvio may be the right option for your patients but are concerned about coverage, you should know that Entyvio is covered by 99% of commercial insurance plans.1*

Also, 92.2% of benefits investigations conducted by Entyvio Connect have identified patient coverage for Entyvio.1†

Entyvio Connect, an assistance program that offers individualized support from case managers familiar with your office information and needs, will help you help your patients take advantage of the financial assistance options they may qualify for. See below for more information.

*
As of October 31, 2016.
Benefits Investigations December 9, 2015 through December 9, 2016.

Connect with support

Entyvio Connect is an assistance program that puts you in touch with insurance and financial case managers. A team will be dedicated to your account, so you can expect individualized support from specialists familiar with your office information and needs.

  • Tailored access and reimbursement information for your patients and office
  • Expertise in local coverage and reimbursement policies

Case managers are trained to provide:

Insurance verification support

Case managers connect directly with insurers to help verify patient coverage and out-of-pocket (OOP) costs for Entyvio.

Prior authorization (PA) and appeals support

Case managers can identify plan-specific PA requirements to help your office obtain authorization before treatment.

Billing and coding support

Case managers respond with timely answers to billing and coding questions, helping to facilitate claims submissions.

Patient financial assistance

Case managers can inform you about financial assistance options for eligible patients and enroll patients into appropriate programs.

Register for exclusive access to interactive articles, the Entyvio in Practice clinical video series, and other resources for your practice.

IMPORTANT SAFETY INFORMATION

Expand
  • ENTYVIO (vedolizumab) for injection is contraindicated in patients who have had a known serious or severe hypersensitivity reaction to ENTYVIO or any of its excipients.
  • Infusion‐related reactions and hypersensitivity reactions including anaphylaxis have occurred. Allergic reactions including dyspnea, bronchospasm, urticaria, flushing, rash, and increased blood pressure and heart rate have also been observed. If anaphylaxis or other serious allergic reactions occur, discontinue administration of ENTYVIO immediately and initiate appropriate treatment.
  • Patients treated with ENTYVIO are at increased risk for developing infections. Serious infections have been reported in patients treated with ENTYVIO, including anal abscess, sepsis (some fatal), tuberculosis, salmonella sepsis, Listeria meningitis, giardiasis, and cytomegaloviral colitis. ENTYVIO is not recommended in patients with active, severe infections until the infections are controlled. Consider withholding ENTYVIO in patients who develop a severe infection while on treatment with ENTYVIO. Exercise caution in patients with a history of recurring severe infections. Consider screening for tuberculosis (TB) according to the local practice.
  • Although no cases of PML have been observed in ENTYVIO clinical trials, JC virus infection resulting in progressive multifocal leukoencephalopathy (PML) and death has occurred in patients treated with another integrin receptor antagonist. A risk of PML cannot be ruled out. Monitor patients for any new or worsening neurological signs or symptoms. Typical signs and symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes. If PML is suspected, withhold dosing with ENTYVIO and refer to a neurologist; if confirmed, discontinue ENTYVIO dosing permanently.
  • There have been reports of elevations of transaminase and/or bilirubin in patients receiving ENTYVIO. ENTYVIO should be discontinued in patients with jaundice or other evidence of significant liver injury.
  • Prior to initiating treatment with ENTYVIO, all patients should be brought up to date with all immunizations according to current immunization guidelines. Patients receiving ENTYVIO may receive non‐live vaccines and may receive live vaccines if the benefits outweigh the risks.
  • Most common adverse reactions (incidence ≥3% and ≥1% higher than placebo): nasopharyngitis, headache, arthralgia, nausea, pyrexia, upper respiratory tract infection, fatigue, cough, bronchitis, influenza, back pain, rash, pruritus, sinusitis, oropharyngeal pain, and pain in extremities.

Indications

Adult Ulcerative Colitis (UC)

ENTYVIO (vedolizumab) is indicated in adult patients with moderately to severely active UC who have had an inadequate response with, lost response to, or were intolerant to a tumor necrosis factor (TNF) blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids for inducing and maintaining clinical response, inducing and maintaining clinical remission, improving endoscopic appearance of the mucosa, and achieving corticosteroid‐free remission.

Adult Crohn’s Disease (CD)

ENTYVIO (vedolizumab) is indicated in adult patients with moderately to severely active CD who have had an inadequate response with, lost response to, or were intolerant to a TNF blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids for achieving clinical response, achieving clinical remission, and achieving corticosteroid‐free remission.

Please see full Prescribing Information, including Medication Guide.

You are about to leave this website.

By clicking “Continue” you will leave this site and enter TakedaMedConnect.com. The information contained on Takeda MedConnect is intended for U.S. healthcare professionals only in response to a specific request for medical information.